TransCode Therapeutics, Inc.
RNAZNASDAQHealthcareBiotechnology
Previous close
$2.87
−$0.10 · -3.37%
Pre-market
$2.972
+$0.102 · +3.55%
Aug 24, 7:48 AM ET
RNAZ company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
44
Fair Value
Momentum
55
Neutral
Sentiment
54
Mixed
Risk resilience
26
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteTransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Philippe Calais
- Listed since
- Jul 8, 2021
- Employees
- 12
Market position
Day range
Current $2.87
52-week range
Current $2.87
- Open
- $2.94
- Previous close
- $2.97
- Volume
- 42.18K
- 0.87× average
- Average volume
- 48.33K
- Average daily volume
- Market cap
- 3.04M USD
- Beta
- 1.24
- Market reference 1
- 50-day average
- $5.7415
- -50.01% below average
- 200-day average
- $7.7843
- -63.13% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -13.1M USD
- P/E (TTM)
- -0.06×
- P/B (TTM)
- 0.02×
- P/S (TTM)
- 0×
- EV / EBITDA
- 0.38×
- Earnings yield
- -735.79%
- Free cash flow yield
- -414.43%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -335.36%
- Return on assets
- -21.34%
- Return on invested capital
- -17.61%
Financial health
- Debt / equity
- 4.72×
- Current ratio
- 6.29×
- Altman Z-score
- -44.88
- Piotroski F-score
- 0 of 9
Financial statements
Income trends
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Cost of goods sold | — | 534.86K USD | 516.75K USD | 98.61K USD | 42.47K USD |
| Gross profit | — | −534.86K USD | −516.75K USD | −98.61K USD | −42.47K USD |
| Research and development | 13.42M USD | 9.62M USD | 12.26M USD | 10.23M USD | 2.75M USD |
| Selling, general, and administrative | 5.77M USD | 5.51M USD | 6.64M USD | 8.33M USD | 3.35M USD |
| Operating expenses | 27.98M USD | 15.13M USD | 18.9M USD | 18.57M USD | 6.11M USD |
| Interest income | 79.2K USD | 684 USD | 5.29K USD | 20.41K USD | 664 USD |
| Interest expense | 6.62K USD | 26.81K USD | 55.9K USD | 17.56M USD | 95.07K USD |
| Depreciation and amortization | 114.18K USD | 534.86K USD | 516.75K USD | 98.61K USD | 42.47K USD |
| Operating income | −27.98M USD | −15.66M USD | −19.42M USD | −18.67M USD | −6.15M USD |
| Net income | −34.66M USD | −16.75M USD | −18.55M USD | −17.56M USD | −6.84M USD |
Company facts updated Aug 24, 2026.
Earnings
- EPS beat rate
- 44%
- 4 beats, 5 misses, 0 met estimates
- Average EPS surprise
- -404.91%
- 9 comparable reports
- Latest EPS result
- -7.17
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Recent analyst actions
RNAZ news
Corporate actions
Corporate action history
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | May 15, 2025 | 1:28 | — | — |
Stock split | Dec 4, 2024 | 1:33 | — | — |
Stock split | Jan 16, 2024 | 1:40 | — | — |
Stock split | May 23, 2023 | 1:20 | — | — |
Effective May 15, 2025
1:28
Effective Dec 4, 2024
1:33
Effective Jan 16, 2024
1:40
Effective May 23, 2023
1:20
RNAZ peers
ETFs holding RNAZ
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research RNAZresearch.disclaimer